Patiromer Enables The Initiation Of Mineralocorticoid Receptor Antagonists (MRAs) For Heart Failure With Reduced Ejection Fraction (HFrEF) In Patients With Hyperkalemia (HK) Or Previous HK: Post HocAnalysis Of The DIAMOND Trial

Bertram Pitt,Stefan Anker,Andrew Coats,Lars Lund,Gerasimos Filippatos,Patrick Rossignol,Matthew Weir,Sandra Wächter,Jeffrey Budden,Javed Butler

DOI: https://doi.org/10.1016/j.cardfail.2023.10.295

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction MRAs are underutilized in patients with HFrEF despite overwhelming data demonstrating reductions in hospitalizations and death. HK or fear of HK is a leading reason for not initiating or discontinuing treatment with MRAs. Objectives To assess whether, in the run-in phase of the DIAMOND trial, where all patients received the novel potassium binder patiromer, patients were able to initiate treatment with an MRA in HFrEF regardless of whether they had current HK or a history of HK. Methods Patients with HFrEF and current or previous HK entered a run-in phase with patiromer-facilitated renin-angiotensin system inhibitors (RASi)/MRA optimization (up-titration to ≥50% recommended dose of RASi and 50 mg of MRA). Patients achieving normokalaemia while receiving specified doses of RASi/MRA were randomized to withdraw or continue patiromer (randomized group). Results A total of 1038 patients completed the run-in phase (422 with HK at screening and 616 with previous HK), of which 878 (85%) were randomized. At screening, rates of no MRA use were higher in the previous HK group (N=252, 40.9%) vs the current HK group (N=132, 31.2%) (Figure 1). During the patiromer-facilitated run-in, the percentage of patients not receiving an MRA declined in both the randomized group (change: N=319 to N=1, 36.3% to 0.1%), and the group of patients failing run-in (not able to achieve randomization criteria [change: N=63 to N=27, 39.3% to 16.1%]). Conclusion The majority of patients with HFrEF receiving no MRA therapy due to previous or current HK, can have MRA therapy optimized with patiromer, regardless of whether they have HK at treatment initiation.

cardiac & cardiovascular systems